Immunwork, Inc. is a privately held biotech company focusing on the research, development, and commercialization of novel drugs to fulfill unmet medical needs.
Our drugs are created based on our proprietary technology platform for treating multiple types of cancer, diabetes, obesity, non-alcoholic steatohepatitis (NASH), pathological blood clots, and other selected severe clinical conditions. Our unique platform allows us to design and generate novel “T-E” drug molecules, which contain targeting (T) and effector (E) moieties. These designs would help to improve the efficacy and limit toxicity. The majority of our T-E drugs are based on “multi-arm linkers” and various “drug bundles”. These drug candidates include antibody-drug conjugates (ADCs), antibody-radionuclide conjugates (ARCs), ultra-long-acting therapeutic peptides, and drugs in other modalities. Six of the drug candidates have been selected and progressed into the pre-clinical development stage. Meanwhile, we are looking forward to applying the multi-arm linker platform for designing additional novel drug candidates.
-
產業
-
生物科技
-
公司規模
-
11-50 名員工
-
總部
-
Taipei
-
類型
-
私人所有
-
創立時間
-
2014
-
專長
-
antibody-drug conjugate、therapeutic peptides、radioimmunotherapy、bioconjugation、multi-arm linkers和biotechnology
